Clinical trial
Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease
NCT07697547 is registered in ClinicalTrials.gov with Shanghai 10th People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease
- Lead sponsor
- Shanghai 10th People's Hospital
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 1, 2023
- Completion date
- March 31, 2026
- Enrollment
- 84 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
crohn's disease, inflammatory bowel disease (ibd)